1. A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Issue 8 (4th March 2013) Authors: Ferrannini, E.; Seman, L.; Seewaldt‐Becker, E.; Hantel, S.; Pinnetti, S.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 8(2013:Aug.) Page Start: 721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose‐finding study. Issue 5 (7th December 2012) Authors: Wilding, J. P. H.; Ferrannini, E.; Fonseca, V. A.; Wilpshaar, W.; Dhanjal, P.; Houzer, A. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 5(2013:May) Page Start: 403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Metabolomic profile of morbidly obese NAFLD: effect of weight loss by exenatide or diet. (February 2019) Authors: Patrício, B.; Gaggini, M.; Carli, F.; Astiarraga, B.; Rosso, C.; Ferrannini, E.; Bugianesi, E.; Camastra, S.; Gastaldelli, A. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The amino acid response to a mixed meal in patients with type 2 diabetes: effect of sitagliptin treatment. Issue 11 (4th August 2014) Authors: Muscelli, E.; Frascerra, S.; Casolaro, A.; Baldi, S.; Mari, A.; Gall, W.; Cobb, J.; Ferrannini, E. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 11(2014:Nov.) Page Start: 1140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗